The short answer
- Ozempic contains semaglutide but is approved for specific uses in adults with type 2 diabetes—not as a weight-loss drug.
- Wegovy contains semaglutide and is approved for chronic weight management in eligible patients, with additional cardiovascular-risk-reduction indications.
- Zepbound contains tirzepatide, acts at GIP and GLP-1 receptors and is approved for chronic weight management in eligible patients; it also has an obstructive-sleep-apnea indication for certain adults with obesity.
- The “best” option depends on diagnosis, medical history, pregnancy plans, side effects, access, cost and willingness to plan for long-term care.
Social media can make these medicines look like three versions of the same shortcut. They are not. Ozempic and Wegovy share an active ingredient but have different approved uses and dosing products. Zepbound uses a different active ingredient and targets two hormone receptors. All require clinical screening, and none turns a trial average into a promise.
The comparison also matters specifically for women because pregnancy planning, contraception, fertility changes after weight loss, gallbladder risk and the preservation of muscle and bone are not footnotes. They belong in the decision from the beginning.
First, the names and ingredients
| Brand | Active ingredient | What the 2026 FDA labeling distinguishes |
|---|---|---|
| Ozempic | Semaglutide; GLP-1 receptor agonist | Adult type 2 diabetes indications include glycemic control and certain cardiovascular and kidney-risk outcomes. It is not FDA-approved specifically for weight loss. |
| Wegovy | Semaglutide; GLP-1 receptor agonist | Chronic weight reduction and maintenance for eligible patients, plus reduction of major cardiovascular events in certain adults with cardiovascular disease and overweight or obesity. Current labeling includes formulation-specific instructions. |
| Zepbound | Tirzepatide; GIP and GLP-1 receptor agonist | Chronic weight reduction and maintenance for eligible patients, and treatment of moderate-to-severe obstructive sleep apnea in certain adults with obesity. |
“Off-label” use means a clinician prescribes an approved medicine for a purpose not included in its FDA labeling. Off-label prescribing can be legal and clinically appropriate, but a patient should understand that distinction. An online seller calling Ozempic “FDA-approved for weight loss” is erasing it.
Who may meet weight-management indications?
For chronic weight management, FDA labeling generally describes adults with obesity, or adults with overweight plus at least one weight-related condition, in addition to a reduced-calorie diet and increased physical activity. Labels use body-mass-index thresholds, but BMI is a screening measure—not a complete account of health, body composition or individual goals.
Eligibility is only the start. A clinician should review pancreatitis history, gallbladder disease, severe gastrointestinal symptoms, kidney risk related to dehydration, diabetic retinopathy when diabetes is present, hypoglycemia risk with certain diabetes medicines, upcoming anesthesia or procedures, and other medications that may be affected by slowed gastric emptying.
All three products carry a boxed warning related to thyroid C-cell tumors observed in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A label warning is not something a telehealth intake should rush past.
What do the weight-loss trials actually show?
In STEP 1, adults with overweight or obesity without diabetes who received weekly semaglutide 2.4 mg plus lifestyle intervention lost an average of 14.9 percent of body weight at 68 weeks, compared with 2.4 percent in the placebo group. In SURMOUNT-1, average loss with tirzepatide at 72 weeks ranged from 15.0 percent to 20.9 percent across the studied maintenance doses, compared with 3.1 percent with placebo.
The head-to-head SURMOUNT-5 trial later found greater average weight reduction with tirzepatide than semaglutide in adults with obesity without diabetes at 72 weeks. That is useful comparative evidence, not a declaration that every patient should choose tirzepatide. Trial populations have inclusion criteria, treatment is supervised, adherence varies and individual responses overlap.
A good choice is one you are eligible to use, can access safely, tolerate, afford and monitor over time. A larger trial mean cannot compensate for a contraindication, a serious adverse effect or a treatment that disappears when temporary pricing ends.
Side effects and safety conversations
Nausea, diarrhea, vomiting, constipation and abdominal discomfort are common across these medicines, especially during dose escalation. Smaller meals, attention to hydration and clinician-guided escalation may help, but severe or persistent symptoms need assessment. Repeated vomiting can contribute to dehydration and kidney injury.
Patients should know the warning signs their prescriber wants reported promptly. Those may include severe persistent abdominal pain, symptoms of gallbladder disease, allergic reaction, significant dehydration, vision changes in a person with diabetes or concerning hypoglycemia when combined with insulin or a sulfonylurea. These medications also delay gastric emptying, so the anesthesia team should know about their use before a procedure.
Compounded or counterfeit products add another layer of risk. FDA-approved medicines have product-specific manufacturing and labeling controls. If a medication arrives with unclear sourcing, unfamiliar concentration instructions or pressure to calculate a dose from an unverified vial, pause and involve a licensed pharmacist or prescriber.
Pregnancy, fertility and contraception: the conversation women should not skip
Weight-loss medication is not used during pregnancy because intentional weight loss offers no benefit to a pregnant patient and may cause fetal harm. Current semaglutide labeling instructs patients to stop the medicine at least two months before a planned pregnancy because of its long washout period. Anyone who is pregnant, may be pregnant or is planning pregnancy should contact the prescriber rather than simply following internet timing advice.
Tirzepatide can affect absorption of oral hormonal contraceptives. Current Zepbound labeling advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after initiation and for four weeks after each dose escalation. A clinician can help select an option that fits the patient.
Fertility can also change indirectly. For some women, improvements in metabolic health or weight may make ovulation more regular. That makes pregnancy planning relevant even when pregnancy previously seemed unlikely. Breastfeeding decisions require individualized discussion because available data and product recommendations matter.
Muscle, nutrition and the quality of weight loss
A smaller appetite can make it easier to eat less, but it can also make it easier to under-consume protein, fluids or micronutrients. Weight loss includes some lean tissue as well as fat. Women—especially in midlife and older age—should discuss adequate nutrition, progressive resistance training and appropriate monitoring rather than treating appetite suppression as the whole plan.
Red flags include persistent inability to eat, dizziness, dehydration, rapid functional decline or a pattern of severe restriction. A registered dietitian can be especially helpful for people with diabetes, kidney disease, gastrointestinal conditions, prior bariatric surgery or a history of disordered eating.
Cost, coverage and the long-term plan
Coverage differs by diagnosis, employer plan and insurer, and it can change. A medicine that is financially reachable for one person may be inaccessible for another. Before starting, ask what documentation is needed, what happens if prior authorization is denied, whether the quoted cost is introductory and what alternatives exist.
Also ask what maintenance means. Obesity is commonly managed as a chronic condition, and weight regain after medication discontinuation is common. That does not mean every person uses the same drug forever. It means stopping, switching or reducing treatment should be planned with realistic expectations and ongoing behavioral support.
A decision framework to bring to your clinician
- Clarify the goal. Is the priority weight management, diabetes outcomes, cardiovascular risk, sleep apnea, mobility or several concerns?
- Confirm the indication. Ask which FDA-approved use applies to you and whether a proposed use is off-label.
- Review exclusions and cautions. Include thyroid-cancer history, pancreatitis, gallbladder and gastrointestinal issues, kidney risk, diabetes complications and planned procedures.
- Discuss reproductive plans. Cover pregnancy timing, contraception, fertility and breastfeeding before the first dose.
- Plan nutrition and strength. Decide how you will protect intake, hydration, muscle and function.
- Map access. Verify coverage, pharmacy supply, follow-up frequency and the plan if cost or tolerance changes.
- Define success and stopping rules. Agree on clinical markers, side-effect thresholds and when another approach should be considered.
So which one is “best”?
There is no responsible one-word answer. For a person with type 2 diabetes and particular cardiovascular or kidney risks, the relevant Ozempic indications may shape the conversation. For chronic weight management, Wegovy and Zepbound are labeled options for eligible patients, but their mechanisms, evidence, side-effect experience, access and patient-specific cautions differ.
The safest conclusion is also the most useful: choose a qualified clinician, insist on the exact product and indication, disclose pregnancy and procedure plans, understand that trial averages are not guarantees and decide how treatment fits a durable nutrition, movement and maintenance plan.